Annexon Biosciences Closes $34M Series A Funding for Neurodegenerative and Autoimmune Disease Therapy

Redwood City, California-based Annexon Biosciences has closed a $34M Series A financing round to develop their lead candidate, ANX005, for treating autoimmune and neurodegenerative diseases. The company was established in 2011 by Ben Barres of Stanford University School of Medicine and Arnon Rosenthal, co-founder of Alector and Rinat Neurosciences. ANX005 is a monoclonal antibody that inhibits the classical complement cascade, an important player not only in autoimmunity but also in the response of the aging brain to stress. Annexon will initially focus on rapidly advancing this candidate therapy for Huntington’s disease.

Redwood City, California-based Annexon Biosciences has closed a $34M Series A financing round to develop their lead candidate, ANX005, for treating autoimmune and neurodegenerative diseases. The company was established in 2011 by Ben Barres of Stanford University School of Medicine and Arnon Rosenthal, co-founder of Alector and Rinat Neurosciences. ANX005 is a monoclonal antibody that inhibits the classical complement cascade, an important player not only in autoimmunity but also in the response of the aging brain to stress. Annexon will initially focus on rapidly advancing this candidate therapy for Huntington’s disease.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail